Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 22;13(1):79.
doi: 10.3390/jcm13010079.

The Role of Immunoglobulin G4 in Outcomes of Primary Sclerosing Cholangitis

Miroslav Vujasinovic  1   2 , Karouk Said  1 , Christina Villard  2   3 , Jennifer Carlsson  4 , Christopher Poli  2 , Patrick Maisonneuve  5 , J-Matthias Löhr  1   6
Affiliations

The Role of Immunoglobulin G4 in Outcomes of Primary Sclerosing Cholangitis

Miroslav Vujasinovic et al. J Clin Med. .

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease that is characterized by an inflammatory and fibrotic process affecting bile ducts which eventually develops into liver cirrhosis and liver failure. The aim of this study was to investigate serum IgG subclass distribution in patients with PSC and its possible association with PSC outcomes.

Patients and methods: We performed a retrospective analysis of 181 patients who had been diagnosed with PSC between January 1970 and December 2015 and followed at our outpatient clinic. Their demographic, immunological, and clinical characteristics were recorded and analyzed.

Results: This study included 181 patients with PSC (120 males, 61 females). There was no association between IgGs and the development of autoimmune hepatitis, cirrhosis, cholangiocarcinoma, liver transplantation, inflammatory bowel disease, and colectomy. Patients with elevated IgG4 had statistically significant higher rates of cholangitis (p = 0.02) and endoscopic retrograde cholangiopancreatography (ERCP) (p = 0.009). High IgG4 values were observed in nine patients who underwent ERCP. In these nine patients, on average, IgG4 was evaluated 5 years after ERCP (min 3 days, max 11 years). Subanalysis considering only IgG4 values evaluated before ERCP showed no significant difference but remains significant if we consider IgG4 values after ERCP.

Conclusion: Elevated IgG4 in our study showed a possible association with higher rates of cholangitis and ERCP among patients with primary sclerosing cholangitis. It seems that IgGs may be a useful tool for the prediction of outcomes in patients with PSC. A prospective study is necessary, especially to study the trends of IgGs values during disease as well as the role of possible seroconversion.

Keywords: IgG; cholangitis; immunoglobulin; primary; sclerosing; subclasses.

PubMed Disclaimer

Conflict of interest statement

M.V.: Abbott (lecture fee), Viatris (lecture fee); K.S.: none; C.V.: none; J.C.: none; C.P.: none; P.M.: none; J.M.L.: Abbott (lecture fee), Viatris (lecture fee).

Figures

Figure 1
Figure 1
Immunoglobulin subclass (IgGs) levels according to age at diagnosis of primary sclerosing cholangitis (PSC).
Figure 2
Figure 2
Liver cirrhosis, autoimmune hepatitis, cholangiocarcinoma, IBD, liver transplantation, and colectomy at or after diagnosis of primary sclerosing cholangitis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J. Hepatol. 2009;51:237–267. doi: 10.1016/j.jhep.2009.04.009. - DOI - PubMed
    1. Manganis C.D., Chapman R.W., Culver E.L. Review of primary sclerosing cholangitis with increased IgG4 levels. World J. Gastroenterol. 2020;26:3126–3144. doi: 10.3748/wjg.v26.i23.3126. - DOI - PMC - PubMed
    1. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Lööf L., Danielsson A., Hultcrantz R., Lindgren S., Prytz H., Sandberg-Gertzén H., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol. 2002;36:321–327. doi: 10.1016/S0168-8278(01)00288-4. - DOI - PubMed
    1. Boberg K.M., Fausa O., Haaland T., Holter E., Mellbye O.J., Spurkland A., Schrumpf E. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369–1376. doi: 10.1002/hep.510230612. - DOI - PubMed
    1. Vujasinovic M., Maier P., Maetzel H., Valente R., Pozzi-Mucelli R., Moro C.F., Haas S.L., Said K., Verbeke C.S., Maisonneuve P., et al. Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis. United Eur. Gastroenterol. J. 2020;8:584–593. doi: 10.1177/2050640620916027. - DOI - PMC - PubMed

LinkOut - more resources